Trade Vor Biopharma Inc. - VOR CFD

Add to favourite

1.91

4.95%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.05

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	1.82
Open*	1.76
1-Year Change*	-61.23%
Day's Range*	1.76 - 1.96
52 wk Range	1.62-7.57
Average Volume (10 days)	196.00K
Average Volume (3 months)	2.30M
Market Cap	119.34M
P/E Ratio	-100.00K
Shares Outstanding	67.81M
Revenue	N/A
EPS	-1.89
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	Mar 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Dec 1, 2023	1.91	0.15	8.52%	1.76	1.97	1.76
Nov 30, 2023	1.82	0.06	3.41%	1.76	1.84	1.71
Nov 29, 2023	1.78	-0.02	-1.11%	1.80	1.86	1.73
Nov 28, 2023	1.79	-0.02	-1.10%	1.81	1.88	1.78
Nov 27, 2023	1.86	0.06	3.33%	1.80	1.87	1.79
Nov 24, 2023	1.79	0.03	1.70%	1.76	1.84	1.76
Nov 22, 2023	1.74	-0.04	-2.25%	1.78	1.78	1.66
Nov 21, 2023	1.75	0.08	4.79%	1.67	1.79	1.60
Nov 20, 2023	1.66	-0.09	-5.14%	1.75	1.75	1.61
Nov 17, 2023	1.73	-0.02	-1.14%	1.75	1.77	1.70
Nov 16, 2023	1.73	-0.04	-2.26%	1.77	1.79	1.65
Nov 15, 2023	1.76	-0.14	-7.37%	1.90	1.95	1.75
Nov 14, 2023	1.89	0.09	5.00%	1.80	1.91	1.78
Nov 13, 2023	1.77	0.04	2.31%	1.73	1.78	1.68
Nov 10, 2023	1.73	-0.18	-9.42%	1.91	1.98	1.73
Nov 9, 2023	1.83	0.04	2.23%	1.79	1.88	1.68
Nov 8, 2023	1.83	-0.08	-4.19%	1.91	1.94	1.81
Nov 7, 2023	1.96	0.11	5.95%	1.85	1.98	1.77
Nov 6, 2023	1.81	-0.09	-4.74%	1.90	1.99	1.75
Nov 3, 2023	1.86	0.07	3.91%	1.79	1.88	1.62

Vor Biopharma Inc. Events

Time (UTC)	Country	Event
Tuesday, December 5, 2023
Time (UTC) 18:30	Country US	Event Vor Biopharma Inc at JMP Securities Hematology and Oncology Summit (Virtual) Vor Biopharma Inc at JMP Securities Hematology and Oncology Summit (Virtual) Forecast - Previous -
Thursday, March 21, 2024
Time (UTC) 10:59	Country US	Event Q4 2023 Vor Biopharma Inc Earnings Release Q4 2023 Vor Biopharma Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	0	0	0	0
Total Operating Expense	93.418	69.018	43.366	10.417	2.86
Selling/General/Admin. Expenses, Total	28.868	21.489	11.748	4.217	0.427
Research & Development	64.55	47.529	31.618	6.2	2.433
Operating Income	-93.418	-69.018	-43.366	-10.417	-2.86
Interest Income (Expense), Net Non-Operating	1.324	0.119	0.029	-0.422	-1.292
Net Income Before Taxes	-92.094	-68.899	-43.337	-10.839	-4.152
Net Income After Taxes	-92.094	-68.899	-43.337	-10.839	-4.152
Net Income Before Extra. Items	-92.094	-68.899	-43.337	-10.839	-4.152
Net Income	-92.094	-68.899	-43.337	-10.839	-4.152
Total Adjustments to Net Income	0	-1.228	-5.925	-1.773	0
Income Available to Common Excl. Extra. Items	-92.094	-70.127	-49.262	-12.612	-4.152
Income Available to Common Incl. Extra. Items	-92.094	-70.127	-49.262	-12.612	-4.152
Diluted Net Income	-92.094	-70.127	-49.262	-12.612	-4.152
Diluted Weighted Average Shares	39.5514	33.4332	35.6459	35.6459	35.6459
Diluted EPS Excluding Extraordinary Items	-2.32846	-2.09752	-1.38198	-0.35381	-0.11648
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-2.32846	-2.09752	-1.38198	-0.35381	-0.11648

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	32.174	30.422	24.725	24.101	21.792
Selling/General/Admin. Expenses, Total	8.277	8.507	7.663	7.226	6.459
Research & Development	23.897	21.915	17.062	16.875	15.333
Operating Income	-32.174	-30.422	-24.725	-24.101	-21.792
Interest Income (Expense), Net Non-Operating	2.195	1.989	0.815	0.313	0.133
Net Income Before Taxes	-29.979	-28.433	-23.91	-23.788	-21.659
Net Income After Taxes	-29.979	-28.433	-23.91	-23.788	-21.659
Net Income Before Extra. Items	-29.979	-28.433	-23.91	-23.788	-21.659
Net Income	-29.979	-28.433	-23.91	-23.788	-21.659
Total Adjustments to Net Income			0	0	0
Income Available to Common Excl. Extra. Items	-29.979	-28.433	-23.91	-23.788	-21.659
Income Available to Common Incl. Extra. Items	-29.979	-28.433	-23.91	-23.788	-21.659
Diluted Net Income	-29.979	-28.433	-23.91	-23.788	-21.659
Diluted Weighted Average Shares	67.0331	66.2657	45.4583	38.009	37.4371
Diluted EPS Excluding Extraordinary Items	-0.44723	-0.42908	-0.52598	-0.62585	-0.57854
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.44723	-0.42908	-0.52598	-0.62585	-0.57854

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	236.95	214.399	49.106	7.539	0.936
Cash and Short Term Investments	230.245	207.469	48.539	6.466	0.929
Cash & Equivalents	57.706	119.801	48.539	6.466	0.929
Prepaid Expenses	4.368	4.836	0.467	0.868	0.007
Other Current Assets, Total	2.337	2.094	0.1	0.205	0
Total Assets	299.366	242.59	75.908	9.826	1.007
Property/Plant/Equipment, Total - Net	57.078	22.523	21.845	0.728	0.071
Property/Plant/Equipment, Total - Gross	61.688	24.607	22.571	0.849	0.101
Accumulated Depreciation, Total	-4.61	-2.084	-0.726	-0.121	-0.03
Other Long Term Assets, Total	5.338	5.668	4.957	1.559	0
Total Current Liabilities	13.119	10.153	10.207	2.186	7.774
Accounts Payable	1.772	1.545	2.361	0.693	0.038
Accrued Expenses	11.161	8.174	7.123	0.938	0.577
Notes Payable/Short Term Debt	0	0	0	0	4.459
Other Current Liabilities, Total	0.186	0.434	0.723	0.555	2.7
Total Liabilities	48.759	26.327	27.637	2.186	7.774
Total Long Term Debt	0	0	0	0	0
Total Equity	250.607	216.263	48.271	7.64	-6.767
Redeemable Preferred Stock		0	107.336	25.069	0.002
Common Stock	0.007	0.004	0.001	0	0
Additional Paid-In Capital	473.587	346.382	2.158	0.458	0.279
Retained Earnings (Accumulated Deficit)	-222.217	-130.123	-61.224	-17.887	-7.048
Total Liabilities & Shareholders’ Equity	299.366	242.59	75.908	9.826	1.007
Total Common Shares Outstanding	65.9961	37.1747	37.1279	35.6459	35.6459
Other Liabilities, Total	35.64	16.174	17.43
Short Term Investments	172.539	87.668
Preferred Stock - Non Redeemable, Net		0
Unrealized Gain (Loss)	-0.77

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	164.438	191.393	216.898	236.95	142.729
Cash and Short Term Investments	160.098	186.902	210.2	230.245	136.067
Cash & Equivalents	45.026	32.212	42.455	57.706	60.827
Prepaid Expenses	3.673	3.952	6.239	4.368	4.891
Other Current Assets, Total	0.667	0.539	0.459	2.337	1.771
Total Assets	223.023	250.986	277.533	299.366	206.373
Property/Plant/Equipment, Total - Net	52.086	53.912	55.431	57.078	58.353
Property/Plant/Equipment, Total - Gross	59.284	60.219	60.877	61.688	62.33
Accumulated Depreciation, Total	-7.198	-6.307	-5.446	-4.61	-3.977
Other Long Term Assets, Total	6.499	5.681	5.204	5.338	5.291
Total Current Liabilities	15.388	12.717	12.579	13.119	11.102
Accounts Payable	1.309	1.648	3.216	1.772	0.824
Accrued Expenses	14.017	10.947	9.198	11.161	10.045
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.062	0.122	0.165	0.186	0.233
Total Liabilities	48.242	46.536	47.318	48.759	47.639
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total	32.854	33.819	34.739	35.64	36.537
Total Equity	174.781	204.45	230.215	250.607	158.734
Redeemable Preferred Stock
Common Stock	0.007	0.007	0.007	0.007	0.004
Additional Paid-In Capital	488.873	485.508	481.032	473.587	358.215
Retained Earnings (Accumulated Deficit)	-313.819	-280.629	-250.65	-222.217	-198.307
Total Liabilities & Shareholders’ Equity	223.023	250.986	277.533	299.366	206.373
Total Common Shares Outstanding	67.7855	67.4336	66.9349	65.9961	38.3932
Short Term Investments	115.072	154.69	167.745	172.539	75.24
Preferred Stock - Non Redeemable, Net
Unrealized Gain (Loss)	-0.28	-0.436	-0.174	-0.77	-1.178

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-92.094	-68.899	-43.337	-10.839	-4.152
Cash From Operating Activities	-85.144	-69.144	-36.292	-9.855	-2.661
Cash From Operating Activities	2.525	1.434	0.605	0.091	0.02
Non-Cash Items	17.118	7.332	2.124	0.748	1.408
Changes in Working Capital	-12.693	-9.011	4.316	0.145	0.063
Cash From Investing Activities	-94.091	-91.651	-4.161	-0.748	0
Capital Expenditures	-8.462	-3.894	-4.161	-0.748	0
Cash From Financing Activities	117.14	232.911	82.526	17.699	2.464
Issuance (Retirement) of Stock, Net	117.14	235.126	82.526	17.699	0
Issuance (Retirement) of Debt, Net				0	2.464
Net Change in Cash	-62.095	72.116	42.073	7.096	-0.197
Other Investing Cash Flow Items, Total	-85.629	-87.757
Financing Cash Flow Items	0	-2.215

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-28.433	-92.094	-68.184	-44.396	-22.737
Cash From Operating Activities	-24.268	-85.144	-66.798	-47.896	-22.904
Cash From Operating Activities	0.837	2.525	1.893	1.001	0.426
Non-Cash Items	4.819	17.118	10.987	6.119	2.731
Changes in Working Capital	-1.491	-12.693	-11.494	-10.62	-3.324
Cash From Investing Activities	6.498	-94.091	2.945	-9.757	-7.055
Capital Expenditures	-0.094	-8.462	-8.141	-7.843	-2.011
Cash From Financing Activities	2.519	117.14	4.879	0.804	0.2
Financing Cash Flow Items	-0.717	0	0	0	0
Issuance (Retirement) of Stock, Net	3.236	117.14	4.879	0.804	0.2
Net Change in Cash	-15.251	-62.095	-58.974	-56.849	-29.759
Other Investing Cash Flow Items, Total	6.592	-85.629	11.086	-1.914	-5.044

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
RA Capital Management, LP	Hedge Fund	33.6827	22748880	0	2023-08-10	LOW
Fidelity Management & Research Company LLC	Investment Advisor	11.2504	7598355	-214681	2023-06-30	LOW
Paradigm BioCapital Advisors LP	Investment Advisor	9.5671	6461467	-16532	2023-06-30	MED
5AM Ventures	Venture Capital	9.4194	6361723	0	2023-06-30	MED
Laurion Capital Management LP	Hedge Fund	4.7127	3182889	0	2023-06-30	HIGH
Invus Public Equities Advisors, LLC	Investment Advisor	3.98	2688015	-104790	2023-06-30	MED
BlackRock Institutional Trust Company, N.A.	Investment Advisor	2.908	1964007	1509942	2023-06-30	LOW
The Vanguard Group, Inc.	Investment Advisor/Hedge Fund	2.5356	1712481	133183	2023-06-30	LOW
Woodline Partners LP	Hedge Fund	1.6452	1111123	0	2023-06-30	HIGH
Johnson & Johnson Innovation-JJDC, Inc.	Venture Capital	1.5912	1074658	0	2023-06-30	LOW
Geode Capital Management, L.L.C.	Investment Advisor/Hedge Fund	1.0696	722405	406458	2023-06-30	LOW
Baker Bros. Advisors LP	Hedge Fund	0.9385	633848	0	2023-06-30	LOW
State Street Global Advisors (US)	Investment Advisor/Hedge Fund	0.9317	629286	578173	2023-06-30	LOW
Sarissa Capital Management, L.P.	Hedge Fund	0.915	618000	0	2023-06-30	LOW
Ang (Robert M.D.)	Individual Investor	0.585	395070	-12657	2023-09-01	LOW
OUP Management Co., LLC	Venture Capital	0.5548	374714	0	2023-06-30	LOW
Ensign Peak Advisors, Inc.	Foundation	0.5124	346087	0	2023-06-30	LOW
Thrivent Asset Management, LLC	Investment Advisor	0.4629	312652	-2557	2023-06-30	LOW
Northern Trust Investments, Inc.	Investment Advisor/Hedge Fund	0.4485	302878	242434	2023-06-30	LOW
Bellecapital Partners AG	Investment Advisor/Hedge Fund	0.1876	126726	0	2023-02-28	LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vor Biopharma Inc. Company profile

About Vor Biopharma Inc

Vor Biopharma Inc is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solution for patients suffering from hematological malignancies. The Company develops engineered hematopoietic stem cell (eHSC) product candidate, VOR33, VCAR33, which together are the treatment paradigm for acute myeloid leukemia (AML) and other hematological malignancies. The Company’s platform provides treatment for both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates (ADCs), bispecific antibodies and CAR-T cell treatments, including CD33 CAR-T. The Company uses genome engineering technology to remove CD33 surface targets from hematopoietic stem cells (HSCs) to create VOR33. The Company’s eHSCs, such as VOR33, are designed to be used with therapeutics such as VCAR33, that would provide tumor-specific killing.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Vor Biopharma Inc revenues was not reported. Net loss applicable to common stockholders increased 65% to $51.9M. Higher net loss reflects Research and development - Balancing val increase of 67% to $33.2M (expense), General and administrative - Balancing increase from $7M to $14.4M (expense), Stock-based Compensation in R&D increase from $374K to $1.6M (expense).

Industry:

Biotechnology & Medical Research (NEC)

100 Cambridgepark Drive
Suite 101
CAMBRIDGE
MASSACHUSETTS 02140
US

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023